Comparison of the effects of latanoprost and travoprost on intraocular pressure in chronic angle-closure glaucoma.

PURPOSE The aim of this study was to compare the intraocular pressure (IOP)-lowering effect of latanoprost and travoprost as primary therapy in patients with chronic angle-closure glaucoma (CACG) after peripheral iridotomy. METHODS Seventy-three (73) CACG patients with IOP>19 mmHg after peripheral iridotomy and without previous antiglaucoma medication were consecutively recruited. CACG was defined as the presence of chronically elevated IOP, glaucomatous optic neuropathy, and a corresponding visual field defect in eyes with occludable angle and peripheral anterior synechiae on gonioscopy. Patients were randomly assigned to 2 groups, based on daily treatment with either latanoprost 0.005% or travoprost 0.004% in the evening for 12 weeks. The IOP was measured at 9 AM and 4 PM at baseline and at 4, 8, and 12 weeks. Between-group differences in mean diurnal IOP and IOP reduction were analyzed. RESULTS After 12 weeks of treatment, mean IOP for both the latanoprost and travoprost groups was significantly reduced, when compared to the baseline IOP (from 21.3+/-1.8 mmHg to 16.0+/-2.3 mmHg and 21.7+/-1.7 to 16.7+/-2.2 mmHg; P<0.001 for both). There was no significant difference in IOP reduction between the 2 treatment groups (P=0.19). At 4 and 8 weeks, the IOP changes from the baseline were statistically significant at all time points for both drugs (all P<0.001). CONCLUSIONS Both latanoprost and travoprost significantly reduced IOP in our sample of CACG patients after peripheral iridotomy.

[1]  H. Taylor,et al.  The prevalence of glaucoma among Eskimos of northwest Alaska. , 1987, Archives of ophthalmology.

[2]  T. Aung,et al.  Intraocular pressure-reducing effects and safety of latanoprost versus timolol in patients with chronic angle-closure glaucoma. , 2004, Ophthalmology.

[3]  R. Parrish,et al.  A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. , 2003, American journal of ophthalmology.

[4]  R. Lai,et al.  The pharmacology of bimatoprost (Lumigan). , 2001, Survey of ophthalmology.

[5]  N. Orzalesi,et al.  Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. , 2006, Ophthalmology (Rochester, Minn.).

[6]  P. Fellenbaum,et al.  A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma , 2003 .

[7]  Tin Aung,et al.  Degree of angle closure and the intraocular pressure-lowering effect of latanoprost in subjects with chronic angle-closure glaucoma. , 2005, Ophthalmology.

[8]  J. Stjernschantz,et al.  Mediation of prostaglandin f2 alpha-induced ocular surface hyperemia by sensory nerves in rabbits. , 1997, Current eye research.

[9]  R. Saxena,et al.  Crossover comparison of timolol and latanoprost in chronic primary angle-closure glaucoma. , 2004, A M A Archives of Ophthalmology.

[10]  N. Congdon,et al.  Screening techniques for angle-closure glaucoma in rural Taiwan. , 2009, Acta ophthalmologica Scandinavica.

[11]  M. Yablonski,et al.  Effects of PhXA41, A New Prostaglandin F2α Analog, on Aqueous Humor Dynamics in Human Eyes , 1993 .

[12]  R. Lowe.  Clinical types of primary angle closure glaucoma. , 1988, Australian and New Zealand journal of ophthalmology.

[13]  P. Kaufman,et al.  Prostaglandin F2α increases uveoscleral outflow in the cynomolgus monkey , 1989 .

[14]  J. Schuman,et al.  One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. , 2002, Archives of ophthalmology.

[15]  S. Gandolfi,et al.  Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension , 2001, Advances in therapy.

[16]  Y. F. Chen,et al.  Efficacy of latanoprost as an adjunct to medical therapy for residual angle-closure glaucoma after iridectomy. , 2000, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[17]  G. Sachs,et al.  Replacement of the carboxylic acid group of prostaglandin F2α with a hydroxyl or methoxy substituent provides biologically unique compounds , 2000, British journal of pharmacology.

[18]  P. Foster,et al.  YAG laser iridotomy treatment for primary angle closure in east Asian eyes , 2000, The British journal of ophthalmology.

[19]  S. Whitcup,et al.  Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension. , 2004, Survey of ophthalmology.

[20]  R. Sihota,et al.  Effect of changing from concomitant timolol pilocarpine to bimatoprost monotherapy on ocular blood flow and IOP in primary chronic angle closure glaucoma. , 2003, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[21]  S. K. Seah,et al.  Acute primary angle closure: configuration of the drainage angle in the first year after laser peripheral iridotomy. , 2004, Ophthalmology.

[22]  H. R. Jung,et al.  Clarifying the nomenclature for primary angle-closure glaucoma. , 1997, Survey of ophthalmology.

[23]  D. Machin,et al.  The prevalence of glaucoma in Chinese residents of Singapore: a cross-sectional population survey of the Tanjong Pagar district. , 2000, Archives of ophthalmology.

[24]  M. Viana,et al.  Association between intraocular pressure peaks and progression of visual field loss. , 1991, Ophthalmology.

[25]  R. Weinreb,et al.  Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. , 1997, Investigative ophthalmology & visual science.

[26]  M. Kook,et al.  Efficacy of latanoprost in patients with chronic angle-closure glaucoma and no visible ciliary-body face: a preliminary study. , 2005, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[27]  C. Kim,et al.  Corneal epithelial cellular dysfunction from benzalkonium chloride (BAC) in vitro , 2004, Clinical & experimental ophthalmology.

[28]  A. Robin,et al.  Argon laser peripheral iridotomies in the treatment of primary angle closure glaucoma. Long-term follow-up. , 1982, Archives of ophthalmology.

[29]  C. Camras.  Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. , 1996, Ophthalmology.

[30]  R. Lowe.  Persistent symptoms after peripheral iridectomy for angle-closure glaucoma. , 1987, Australian and New Zealand journal of ophthalmology.

[31]  S. Asrani,et al.  Large Diurnal Fluctuations in Intraocular Pressure Are an Independent Risk Factor in Patients With Glaucoma , 2000, Journal of glaucoma.

[32]  J. Nordmann,et al.  Comparison of Topical Travoprost Eye Drops Given Once Daily and Timolol 0.5% Given Twice Daily in Patients with Open-Angle Glaucoma or Ocular Hypertension , 2001, Journal of glaucoma.

[33]  R. Weinreb,et al.  Prostaglandin action on ciliary smooth muscle extracellular matrix metabolism: implications for uveoscleral outflow. , 1997, Survey of ophthalmology.

[34]  P. Netland,et al.  Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. , 2001, American journal of ophthalmology.

[35]  P. Kaufman,et al.  Effects of prostaglandins on the aqueous humor outflow pathways. , 2002, Survey of ophthalmology.

[36]  R. Ritch,et al.  Chronic angle-closure with glaucomatous damage: long-term clinical course in a North American population and comparison with an Asian population. , 2002, Ophthalmology.

[37]  T. Aung,et al.  Long-term clinical course of primary angle-closure glaucoma in an Asian population. , 2000, Ophthalmology.

[38]  J. Mcgalliard,et al.  The effect of Nd:YAG iridotomy on intraocular pressure in hypertensive eyes with shallow anterior chambers , 1990, Eye.

[39]  A. Alm,et al.  Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. , 1995, Ophthalmology.

[40]  C. Baudouin,et al.  Comparison of toxicological profiles of benzalkonium chloride and polyquaternium-1: an experimental study. , 2006, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[41]  A. Konstas,et al.  Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma. , 1999, American journal of ophthalmology.

[42]  P. Foster,et al.  Glaucoma in Mongolia. A population-based survey in Hövsgöl province, northern Mongolia. , 1996, Archives of ophthalmology.